Name : Human LY6G6D Protein
Product Source :
Recombinant Human LY6G6D Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Asn20-Ser104.[Accession | O95868]
Molecular Weight :
The protein has a predicted MW of 35.87 kDa. Due to glycosylation, the protein migrates to 40-50 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human LY6G6D on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human LY6G6D is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Human LY6G6D, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-LY6G6D Antibody, hFc Tag with the EC50 of 14.6ng/ml determined by ELISA.
Background :
LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.LY6G6D was identified as a selectively expressed CRC antigen that can be utilized to potently re-direct and activate cytotoxic T-cells to lyse LY6G6D expressing CRC using a TcE. This effect can be spread to target negative neighboring tumor cells, potentially leading to improved therapeutic efficacy.
Synonyms :
Protein Ly6-D; C6orf23; G6D; MEGT1; NG25
References & Citations :
Corrales L, Hipp S, Martin K, Sabarth N, Tirapu I, Fuchs K, Thaler B, Walterskirchen C, Bauer K, Fabits M, Bergmann M, Binder C, Chetta PM, Vogt AB, Adam PJ. LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager. Front Immunol. 2022 Sep 8;13:1008764. doi: 10.3389/fimmu.2022.1008764. PMID: 36159851; PMCID: PMC9493073.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
CA12/Carbonic Anhydrase 12 Protein
Heat Stable FGF-basic Protein
Popular categories:
FGF-2/bFGF
CLCF1